Response to letter regarding article, "patient-reported measures provide unique insights into motor function after stroke". by Stewart, Jill Campbell & Cramer, Steven C
UC Irvine
UC Irvine Previously Published Works
Title
Response to letter regarding article, "patient-reported measures provide unique 
insights into motor function after stroke".
Permalink
https://escholarship.org/uc/item/0889s6nd
Journal
Stroke, 44(7)
ISSN
0039-2499
Authors
Stewart, Jill Campbell
Cramer, Steven C
Publication Date
2013-07-01
DOI
10.1161/strokeaha.113.001705
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
e80
Response to Letter Regarding Article, 
“Patient-Reported Measures Provide Unique 
Insights Into Motor Function After Stroke”
We thank Drs Stinear and Byblow for their kind words. These 
authors identified a compelling message regarding patient strati-
fication from Figure 2 of our prior report: specific ranges of upper 
extremity (UE) Fugl–Meyer (FM) scores correspond to distinct 
UE functional states (see below). This approach provides a 
Rosetta Stone, whereby examination assessments are expressed 
in terms that are clinically meaningful and elegantly simple.
Drs Stinear and Byblow consider use of this approach in the 
setting of clinical care delivery, but its value might also extend 
to clinical trial design, including end points. In some studies, a 
continuous variable used to measure behavior is collapsed into 
a categorical variable. Although doing so can decrease statistical 
power1 and reduce granularity of the measure, this approach can 
be advantageous in certain settings, 2 of which are considered 
below: (1) when the levels of the categorical variable are defined 
in a manner that has strong clinical validity, and (2) when conver-
sion to a categorical variable enables use of a sliding dichotomous 
outcome analysis.
Gait velocity is one example where investigators sometimes 
reduce a continuous measure to a categorical variable, with levels 
that are clinically valid and meaningful. A key rationale for doing 
so is a study by Perry et al,2 who found that self-selected gait 
velocity among ambulatory patients with chronic stroke fell into 
3 categories, each of which is associated with a particular level 
of ambulation:
1.  gait velocity <0.4 m/s, which is associated with ambula-
tion only in home;
2.  gait velocity 0.4 to 0.8 m/s, which is associated with
limited community ambulation;
3.  gait velocity >0.8m/s, which is associated with unlim-
ited community ambulation.
These 3 descriptions of ambulation are simple and compelling 
for patients and practitioners. The idea provided by Drs Stinear 
and Byblow can be rephrased as a suggestion to use this same 
approach for UE (ie, classify UE movement into 1 of 3 simple 
categories according to cutoffs in an examination measure). The 
examination measure for the lower extremity is gait velocity, 
whereas for the UE it is the arm motor FM score, as follows:
1.  FM score 0 to 25, which is associated with UE is not
used.
2.  FM score 26 to 55, which is associated with UE is used,
but at best this is very difficult and very rare.
3.  FM score 56 to 66, which is associated with UE is used,
and generally functional levels.
A second potential implication of this issue for clinical trial 
design relates to sliding dichotomous outcome analysis. This type 
of analysis classifies treatment response dichotomously (ie, as 
successful or not). Importantly, the criteria used to classify treat-
ment response as successful or not differ according to the sever-
ity of stroke. The utility provided a sliding dichotomous outcome 
approach that has been reviewed for acute stroke trials,3 which 
aim to increase the amount of brain tissue that survives and gener-
ally use global outcome measures, and for restorative stroke tri-
als,4 which aim to promote plasticity in surviving brain tissue and 
increasingly use modality-specific outcome measures.5
These ideas require further study. Limitations might be present 
when Stroke Impact Scale and Motor Activity Log measure UE 
usage in patients with more severe impairments. For example, the 
Stroke Impact Scale and Motor Activity Log generally focus on 
unimanual tasks; however, motor rehabilitation with severe motor 
impairments may focus on bimanual task training or on use of the 
paretic UE as an active assist to the less impaired (nonparetic) 
hand; examples include using the nonparetic hand to stabilize 
writing paper or holding a box with the paretic UE to open the 
box using the nonparetic UE. Therefore, measurement of amount 
and difficulty of UE use in such patients could conceivably ben-
efit from addition of measures that attend to this issue. Such mea-
sures would include tasks that are bimanual as well as tasks that 
have the paretic hand used as an active assist.
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